MDM2/p53 Protein Expression in the Development of Colorectal Adenocarcinoma

Journal of Gastrointestinal Surgery

Volumn 4, Issue 1, 2000, Pages 109-114

  Abdel Fattah, Ghada ^a   Yoffe, Boris ^a   Krishnan, Bhuvaneswari ^a   Khaoustov, Vladimir ^a   Itani, Kamal ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Colorectal cancer; Mdm2 oncogene; P53

Indexed keywords

MDM2 PROTEIN, HUMAN; MDM2 PROTEIN, MOUSE; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; TUMOR PROTEIN;

ADENOCARCINOMA; ADENOMA; ANIMAL; ARTICLE; COLON; COLORECTAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE;

ADENOCARCINOMA; ADENOMA; ANIMALS; COLON; COLORECTAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033630298     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(00)80041-4     Document Type: Article

References (32)

1. American Cancer Society: Cancer Facts and Figures, 1996. Atlanta: American Cancer Society (ACS), 1996. Publication No. 5008-96.
2. Greenberger NJ. Updates in gastroenterology. Ann Intern Med 1998;129:309-316.
3. Ransohoff DF. Colorectal cancer in digestive disease in the United States: Epidemiology and impact. In Everhart JE, ed. 1994, NIH Publication No. 94-1447 pp 207-223.
4. Boring CC, Squire TS, Tong T, Montgomery S. Cancer Statistics, 1994. CA Cancer J Clin 1994;44:7-26.
5. Agency for Health Care Policy and Research (AHCPR). Research Activities 1997;200:15-18.
6. Fearon ER, Vogelstein B. A genetic model of colorectal tumorigenesis. Cell 1990;61:759-767.
7. Wang XW, Harris CC. p53 tumor-suppressor gene: Clues to molecular carcinogenesis. J Cell Physiol 1997;173:247-255.
8. Cahilly-Snyder L, Yang-Feng T, Franke U, George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from transformed mouse 3T3 cell line. Somat Cell Mol Genet 1987;13:235-244.
9. Valassiadou KE, Stefanaki K, Tzardi M, Datseris G, Georgoulias V, Mellissas J, Tsiftsis DD, Delides G, Kana Varos P. Immunohistochemical expression of p53, mdm2, and wafl/p21 proteins in colorectal adenocarcinomas. Anticancer Res 1997;17:2571-2576.
10. Hao XP, Gunther T, Roessner A, Price AB, Talbott IC: Expression of mdm2 and p53 in epithelial neoplasms of the colorectum. Mol Pathol 1998;51:26-29.
11. Genta RM, Bleyzer I, Cate TR, Tandon AK, Yoffe B, In situ hybridization and immunohistochemical analysis of cytomegalovirus-associated ileal perforation. Gastroenterology 1993;104:1822-1827.
12. Oliner JD, Kinzler KW, Melzer PS, George D, Vogelstein B. Amplification of gene encoding a p53 associated protein in human sarcomas. Nature 1992;358:80-83.
13. Merup M, Juliusson G, Xu XH, Jasson M, Stellan B, Rasool O, Roijer E, Stenman G, Gahrton G, Einhorn S. Amplification of multiple regions of chromosome 12, including 12q13-15, in chronic lymphocytic leukemia. Eur J Hematol 1997;58:174-180.
14. Nilbert M, Rydholm A, Millen H, Mitelman F, Mandahl N. MDM2 gene amplification correlates with ring chromosomes in soft tissue tumors. Genes Chromosomes Cancer 1994;9: 261-265.
15. Ladanyi M, Lewis R, Rhanwar S, Gerald W; Huvos A, Healey J. MDM2 and CDK4 gene amplification in Ewing's sarcoma. J Pathol 1995;53:16-18.
16. Nakayama T, Toguchida J, Wadayama B, Kanoe H, Kotoura Y, Sasalci M. MDM2 gene amplification in bone and soft-tissue tumors: Association with tumor progression in differentiated adipose-tissue tumors. Int J Cancer 1995;64:342-346.
17. Giannikaki E, Kouvidou C, Tzardi M, Stefanaki K, Koutsoubi K, Gregoriou M, Zois E, Kakolyris S. pS3 protein expression in breast carcinoma. Cooperative study with wild type p53 induced proteins MDM2 and p21/WAF1. Anticancer Res 1997;17:2123-2127.
18. Momand J, Zambera GP, Olson DC, George D, Levine AL. The mdm2 oncogene product forms a complex with the pS3 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245.
19. Piette J, Neel H, Marechal V. Mdm2: Keeping p53 under control. Oncogene 1997;15:1001-1010.
20. Higashyama M, Doi O, Ykokouchi H, Kasugal T, Ishiguro S, Takami K, Nakayama T, Nishisho I. MDM2 gene amplification and expression in non-small cell lung cancer: Immunohistochemical expression of its protein is a favorable prognostic marker in patients without p53 accumulation. Br J Cancer 1997;75:1302-1308.
21. Drager BJ, Kushima M, Goebell P, Jax TW, Gerharz CD, Bultel H, Schulz WA, Ebrtn T, Ackermann R. P53 and MDM2 in the development and progression of bladder cancer. Eur Urol 1997;32:487-493.
22. Barnes DM, Hanby AM, Gillett CE, Mohamed S, Hogson S, Bobrow LG, Leigh IM, Purkis T, MacGeoch C, Spurr NK, Bartek J, Vojtesek B, Picksley SM, Lane DP. Abnormal expression of wild type p53 protein in normal cells of cancer family patient. Lancet 1992;340:259-263.
23. Grimm M-O, Jurgens B, Schulz WA, Makri D, Schmitz-Drager BJ. Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. Urol Res 1995;23:293-300.
24. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes rapid degradation of p53. Nature 1997;387:296-299.
25. Barak Y, Juven T, Haffner R, Oren M. MDM2 expression is induced by wild type p53 activity. EMBO J 1993;12:461-468.
26. Juven T, Barak Y, Zauberman A, George D, Oren M. Wild type p53 can mediate sequence specific transactivation of an internal promoter within the mdm2 gene. Oncogene 1993;8: 3411-3416.
27. Khatib Z, Matsushime H, Valentine M, Shapiro D, Sherr C, Look A. Coamplification of the CDK4 gene with MDM2 and GL1 in human sarcomas. Cancer Res 1993;53:5535-5541.
28. DeCaprio JA, Furukawa YK, Ajchenbaum F, Griffin JF, Livingstone DM. The retinoblastoma susceptibility gene produce becomes phosphorylated in multistages during cell cycle entry and progression. Proc Natl Acad Sci 1992;89: 1795-1798.
29. Zhang Y, Xiong Y, Yarbrough Y. ARF-promotes MDM2 degradation and stabilizes p53: ARF-locus deletion impairs both RB and p53 tumor suppressor pathways. Cell 1998;92: 725-734.
30. ARF links the tumour suppressor p53 to Ras. Nature 1998;395:125-126.
31. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA. The INK4a tumor suppressor gene product, p19 Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92:713-723.
32. ARF links the tumour suppressors RB and p53. Nature 1998;395:124-125.